253 related articles for article (PubMed ID: 9504690)
1. Immunohistochemical and two-parameter flow cytometric studies of DNA topoisomerase II alpha in human epithelial ovarian carcinoma and germ cell tumor.
Tanoguchi K; Sasano H; Yabuki N; Kikuchi A; Ito K; Sato S; Yajima A
Mod Pathol; 1998 Feb; 11(2):186-93. PubMed ID: 9504690
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical study of DNA topoisomerase II in human gastric disorders.
Yabuki N; Sasano H; Kato K; Ohara S; Toyota T; Nagura H; Miyaike M; Nozaki N; Kikuchi A
Am J Pathol; 1996 Sep; 149(3):997-1007. PubMed ID: 8780403
[TBL] [Abstract][Full Text] [Related]
3. Topoisomerase II-alpha expression in different cell cycle phases in fresh human breast carcinomas.
Villman K; Ståhl E; Liljegren G; Tidefelt U; Karlsson MG
Mod Pathol; 2002 May; 15(5):486-91. PubMed ID: 12011253
[TBL] [Abstract][Full Text] [Related]
4. DNA topoisomerase II alpha and Ki-67 in human adrenocortical neoplasms: a possible marker of differentiation between adenomas and carcinomas.
Iino K; Sasano H; Yabuki N; Oki Y; Kikuchi A; Yoshimi T; Nagura H
Mod Pathol; 1997 Sep; 10(9):901-7. PubMed ID: 9310953
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of topoisomerase IIalpha (Topo IIalpha) and multidrug resistance-associated protein (MRP), plus chemosensitivity testing, as chemotherapeutic indices of ovarian and endometrial carcinomas.
Koshiyama M; Fujii H; Kinezaki M; Morita Y; Nanno H; Yoshida M
Anticancer Res; 2001; 21(4B):2925-32. PubMed ID: 11712788
[TBL] [Abstract][Full Text] [Related]
6. Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon.
Staley BE; Samowitz WS; Bronstein IB; Holden JA
Mod Pathol; 1999 Apr; 12(4):356-61. PubMed ID: 10229499
[TBL] [Abstract][Full Text] [Related]
7. Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors.
van der Zee AG; de Jong S; Keith WN; Hollema H; Boonstra H; de Vries EG
Cancer Res; 1994 Feb; 54(3):749-55. PubMed ID: 8306337
[TBL] [Abstract][Full Text] [Related]
8. Topoisomerase II alpha expression in esophageal squamous cell carcinoma.
Ohashi Y; Sasano H; Yamaki H; Shizawa S; Kikuchi A; Shineha R; Akaishi T; Satomi S; Nagura H
Anticancer Res; 1999; 19(3A):1873-80. PubMed ID: 10470130
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical study of Ki-67 and DNA topoisomerase II in human endometrium.
Ito K; Sasano H; Yabuki N; Matsunaga G; Sato S; Kikuchi A; Yajima A; Nagura H
Mod Pathol; 1997 Apr; 10(4):289-94. PubMed ID: 9110289
[TBL] [Abstract][Full Text] [Related]
10. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications.
Rudolph P; Olsson H; Bonatz G; Ratjen V; Bolte H; Baldetorp B; Fernö M; Parwaresch R; Alm P
J Pathol; 1999 Jan; 187(2):207-16. PubMed ID: 10365096
[TBL] [Abstract][Full Text] [Related]
11. Correlation between Topo II alpha expression and chemosensitivity testing for Topo II-targeting drugs in gynaecological carcinomas.
Koshiyama M; Fujii H; Kinezaki M; Yoshida M
Anticancer Res; 2001; 21(2A):905-10. PubMed ID: 11396183
[TBL] [Abstract][Full Text] [Related]
12. The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas.
Bar JK; Grelewski P; Noga L; Rabczyński J; Gryboś M; Jeleń M
Adv Clin Exp Med; 2012; 21(1):35-42. PubMed ID: 23214297
[TBL] [Abstract][Full Text] [Related]
13. Topoisomerase II alpha expression in normal, inflammatory, and neoplastic conditions of the gastric and colonic mucosa.
Fogt F; Nikulasson ST; Holden JA; Alder SA; Hallgrimsson J; Jessup MJ; O'Brien MJ; Lavin PT; Goldman H
Mod Pathol; 1997 Apr; 10(4):296-302. PubMed ID: 9110290
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables.
Depowski PL; Rosenthal SI; Brien TP; Stylos S; Johnson RL; Ross JS
Mod Pathol; 2000 May; 13(5):542-7. PubMed ID: 10824926
[TBL] [Abstract][Full Text] [Related]
15. Differential immunohistochemical staining for DNA topoisomerase II alpha and beta in human tissues and for DNA topoisomerase II beta in non-Hodgkin's lymphomas.
Bauman ME; Holden JA; Brown KA; Harker WG; Perkins SL
Mod Pathol; 1997 Mar; 10(3):168-75. PubMed ID: 9071722
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical study on topoisomerase IIalpha, Ki-67 and cytokeratin-19 in oral lichen planus lesions.
Mattila R; Alanen K; Syrjänen S
Arch Dermatol Res; 2007 Jan; 298(8):381-8. PubMed ID: 17072627
[TBL] [Abstract][Full Text] [Related]
17. Drastic reduction of topoisomerase II alpha associated with major acquired resistance to topoisomerase II active agents but minor perturbations of cell growth.
Hashimoto S; Chatterjee S; Ranjit GB; Bao C; Ford J; Ganapathi R; Berger SJ; Berger NA
Oncol Res; 1995; 7(7-8):407-16. PubMed ID: 8747604
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas.
Coleman LW; Bronstein IB; Holden JA
Anticancer Res; 2001; 21(2A):1167-72. PubMed ID: 11396158
[TBL] [Abstract][Full Text] [Related]
19. Expression of cyclooxygenase-2 and DNA topoisomerase II alpha in precancerous and cancerous lesions of the oral mucosa.
Segawa E; Sakurai K; Kishimoto H; Takaoka K; Noguchi K; Hashitani S; Hirota S; Urade M
Oral Oncol; 2008 Jul; 44(7):664-71. PubMed ID: 17996482
[TBL] [Abstract][Full Text] [Related]
20. DNA topoisomerase I and IIalpha expression in penile carcinomas: assessing potential tumour chemosensitivity.
Berney DM; Stankiewicz E; Adlan AM; Kudahetti S; Biedrzycki OJ; Hadway P; Watkin N; Corbishley C
BJU Int; 2008 Sep; 102(8):1040-4. PubMed ID: 18489530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
